Trial Profile

A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Voxelotor (Primary)
Indications Sickle cell anaemia
Focus Therapeutic Use
Acronyms ActIVe
Sponsors Global Blood Therapeutics

Most Recent Events

15 Jun 2023 Results assessing impact of Voxelotor on physical activity, fatigue, and sleep quality presented at the 28th Congress of the European Haematology Association
15 Dec 2022 Status changed from active, no longer recruiting to completed.
13 Dec 2022 Results assessing Hb response, patient-reported quality-of-life (QOL) outcomes, and safety data , presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com